Literature DB >> 20507947

Validity of severity scores in hospitalized patients with nursing home-acquired pneumonia.

Ali A El-Solh1, Ahmad Alhajhusain, Philippe Abou Jaoude, Paul Drinka.   

Abstract

BACKGROUND: Several severity scores have been advanced to predict a patient's outcome from community-acquired pneumonia (CAP). The purpose of this study is to compare the accuracy of confusion, urea, respiratory rate, BP (CURB); CURB plus age ≥ 65 years (CURB-65); CURB-65 minus urea (CRB-65); and systolic BP, oxygenation, age, and respiratory rate (SOAR) scoring systems in predicting 30-day mortality and ICU admission in patients with nursing home-acquired pneumonia (NHAP).
METHODS: A retrospective analysis of a prospectively collected database of 457 nursing home residents hospitalized with pneumonia at two university-affiliated tertiary care facilities. Clinical and laboratory features were used to compute severity scores using the British Thoracic Society severity rules and the SOAR criteria. The sensitivity, specificity, and positive and negative predictive values were compared for need for ICU admission and 30-day mortality.
RESULTS: The overall 30-day mortality and ICU admission rates were 23% and 25%, respectively. CURB, CURB-65, and CRB-65 performed similarly in predicting mortality with areas under the receiver operating characteristic curves (AUCs) of 0.605 (95% CI, 0.559-0.650), 0.593 (95% CI, 0.546-0.638), and 0.592 (95% CI, 0.546-0.638), respectively, whereas SOAR showed superior accuracy with an AUC of 0.765 (95% CI, 0.724-0.803) (P < .001). The need for ICU care was also better identified with the SOAR model compared with the other scoring rules.
CONCLUSIONS: All three British Thoracic Society rules had lower performance accuracy in predicting 30-day mortality of hospitalized NHAP than SOAR. SOAR is also a superior alternative for better identification of severe NHAP. An improved rule for severity assessment of hospitalized NHAP is needed.

Entities:  

Mesh:

Year:  2010        PMID: 20507947     DOI: 10.1378/chest.10-0494

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  7 in total

1.  Application and comparison of scoring indices to predict outcomes in patients with healthcare-associated pneumonia.

Authors:  Wen-Feng Fang; Kuang-Yao Yang; Chieh-Liang Wu; Chong-Jen Yu; Chang-Wen Chen; Chih-Yen Tu; Meng-Chih Lin
Journal:  Crit Care       Date:  2011-01-19       Impact factor: 9.097

Review 2.  Predictors of mortality for nursing home-acquired pneumonia: a systematic review.

Authors:  Naveen Dhawan; Naushira Pandya; Michael Khalili; Manuel Bautista; Anurag Duggal; Jaya Bahl; Vineet Gupta
Journal:  Biomed Res Int       Date:  2015-03-02       Impact factor: 3.411

3.  Incidence of Antibiotic Treatment Failure in Patients with Nursing Home-Acquired Pneumonia and Community Acquired Pneumonia.

Authors:  Mariana Lopes; Gonçalo Alves Silva; Rui Filipe Nogueira; Daniela Marado; João Gonçalves; Carlos Athayde; Dilva Silva; Ana Figueiredo; Jorge Fortuna; Armando Carvalho
Journal:  Infect Dis Rep       Date:  2021-01-05

4.  Value of D-dimer in predicting various clinical outcomes following community-acquired pneumonia: A network meta-analysis.

Authors:  Jiawen Li; Kaiyu Zhou; Hongyu Duan; Peng Yue; Xiaolan Zheng; Lei Liu; Hongyu Liao; Jinlin Wu; Jinhui Li; Yimin Hua; Yifei Li
Journal:  PLoS One       Date:  2022-02-23       Impact factor: 3.240

5.  Nursing home-acquired pneumonia: course and management in the emergency department.

Authors:  Syed Imran Ayaz; Nadia Haque; Claire Pearson; Patrick Medado; Duane Robinson; Robert Wahl; Marcus Zervos; Brian J O'Neil
Journal:  Int J Emerg Med       Date:  2014-05-12

Review 6.  Prognostic value of procalcitonin in pneumonia: A systematic review and meta-analysis.

Authors:  Dan Liu; Long-Xiang Su; Wei Guan; Kun Xiao; Li-Xin Xie
Journal:  Respirology       Date:  2015-12-10       Impact factor: 6.424

Review 7.  Advances in the prevention, management, and treatment of community-acquired pneumonia.

Authors:  Mathias W Pletz; Gernot G Rohde; Tobias Welte; Martin Kolditz; Sebastian Ott
Journal:  F1000Res       Date:  2016-03-08
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.